Last updated: May 20, 2026
Duavee (conjugated estrogens, CEE, plus bazedoxifene) sits in the menopausal hormone therapy space with a differentiated dose-combination profile aimed at preventing osteoporosis while avoiding uterine stimulation when used in women with a uterus. Public clinical-trial activity is limited for new registrational studies; the main “update” is post-approval evidence and ongoing real-world utilization, while the market outlook is driven by competitive substitution within estrogen/bazedoxifene alternatives, payer controls, and persistence.
What is the latest clinical-trials update for Duavee (conjugated estrogens bazedoxifene)
Bottom line: Duavee’s registrational program dates to earlier phases; current public sources show no broad late-stage (Phase 3) expansion trials that materially change label or exclusivity posture.
Are there new Phase 3 trials for Duavee
Answer: No widely indexed Phase 3 trial program is evident in current public registries as a label-expanding effort for Duavee. The observable trial footprint tends to be smaller pharmacovigilance, observational, or secondary analyses rather than new endpoints that would rebase exclusivity.
What kinds of studies still appear for Duavee
Answer: The trial mix typically skews toward:
- Observational outcomes in postmenopausal populations
- Adherence and persistence studies in claims databases
- Safety monitoring and rare event surveillance
- Comparisons against other hormone therapy regimens in real-world cohorts
What endpoints dominate Duavee evidence
Answer: Label-aligned outcomes remain the anchor:
- Bone mineral density and fracture risk proxies
- Uterine safety (endometrial effects)
- Vasomotor symptom effects (when evaluated alongside skeletal indications)
- Thromboembolic and cardiovascular safety signals in postmenopausal use contexts
How big is the Duavee market, who buys it, and what drives demand
Bottom line: Duavee’s market is constrained by a niche positioning within hormone therapy and competition from other estrogen-progestin and selective estrogen receptor modulator (SERM) or tissue-selective estrogen complexes. Demand depends on persistence, payer formulary access, and patient selection aligned to uterine safety goals.
Who is the typical Duavee patient
Answer: Postmenopausal women, including those with a uterus, seeking skeletal protection without conventional progestin exposure. Market access often targets:
- Patients with osteoporosis risk who want an estrogenic approach
- Patients for whom uterine safety is a key decision factor
- Clinically stable users who are already adherent
What drives Duavee utilization in practice
Answer: The main levers are:
- Switching cost for stable patients (persistence reduces churn)
- Formulary coverage and prior authorization patterns
- Side-effect tolerability relative to alternatives
- Physician comfort and familiarity with uterine-safety messaging
What is Duavee’s pricing and revenue exposure versus key competitors
Bottom line: Revenue exposure is sensitive to price concessions and rebate dynamics, not just gross unit demand. Duavee’s competitive set includes other branded and generic menopausal hormone therapy regimens, plus SERMs and SERMs-in-combination approaches.
Competitive landscape: where Duavee is compared
Answer: Typical payer and prescriber comparisons include:
- Estrogen-progestin regimens for endometrial protection
- Other SERM-based or tissue-selective estrogen approaches
- Oral bisphosphonate and other osteoporosis therapies that compete for the “bone protection” budget when estrogen use is not strongly preferred
What matters most for future sales
Answer: In this category, the variables that most affect future sales trajectories are:
- Net price trend driven by payer contracting
- Switchability to generics in competing hormone therapy classes
- Uptake of alternative osteoporosis standards of care that reduce demand for estrogen-based options
When does Duavee lose exclusivity and what does the Orange Book say
Bottom line: Duavee is not a drug with a single clean exclusivity “event” visible from label-level public facts; multiple patent layers typically determine practical entry. The Orange Book governs regulatory exclusivity for specific NDA strengths.
Orange Book status
Answer: The Orange Book listing controls whether generic approvals can reference Duavee and whether patents are listed for the drug product, the drug substance, and/or specific manufacturing/use aspects. Without a complete, enumerated list of each listed patent and its expiration date for the specific Duavee NDA/strength, exclusivity timing cannot be stated as a date-certain business fact.
What patents protect Duavee and how strong is the patent estate
Bottom line: Duavee’s protection typically includes a combination of:
- Composition of matter (active ingredient pairing and/or specific salt/chemical definitions)
- Formulation patents for the drug product
- Method-of-use patents around osteoporosis prevention and/or uterine safety claims
Which claim types tend to matter for generic entry
Answer: For combination products, the most consequential barriers usually include:
- Drug product/formulation patents that constrain “equivalence” design for approval
- Method-of-use patents that shape Paragraph IV litigation leverage when label carveouts are needed
- Manufacturing patents tied to process constraints
How to read “strength” for Duavee in licensing or litigation
Answer: For business planning, patent strength should be assessed by:
- Number of listed patents per NDA strength
- Residual life (years left)
- Expected litigation stickiness from prior enforcement or consistent claim drafting
- Likelihood that a generic can design around listed claims without a label compromise that reduces sales
What Paragraph IV challenges are filed for Duavee and how many generics are at risk
Bottom line: A data-complete assessment requires the Orange Book patent-by-patent status and any pending Paragraph IV notices. Without an enumerated notice and litigation docket set, “how many” and “what stage” cannot be stated as a factual count.
What generic entry risks exist for Duavee
Bottom line: The generic risk profile is driven by:
- Whether relevant patents are still listed and enforceable
- Whether generics must pursue label carveouts that reduce commercial value
- Whether formulation or process constraints create practical IP barriers
What would a generic need to do
Answer: A generic version would generally need:
- FDA approval pathway via ANDA referencing the RLD NDA (with patent certifications per Orange Book listings)
- A formulation/process package that supports bioequivalence and meets regulatory equivalence standards
- An agreed label positioning if method-of-use patents require carveouts
Duavee clinical evidence: what outcomes are validated and what is the current medical position
Bottom line: Duavee’s established role is in postmenopausal skeletal protection and uterine safety positioning. Clinical adoption remains linked to patient selection and persistence rather than new label-changing trial evidence.
What outcomes the Duavee label supports
Answer: The label position is anchored to:
- Osteoporosis prevention/treatment-aligned claims (depending on indication wording)
- Endometrial safety with a uterus
- A risk-benefit profile that is used by prescribers to choose it over alternatives
Market projection for Duavee (3-year and 5-year)
Bottom line: The most likely trajectory is steady-to-moderate decline or flat-to-slow growth depending on net price, payer coverage persistence, and substitution pressure from competing hormone therapy and osteoporosis standards of care. A strict quantitative projection requires current baseline units/revenue, which is not provided in the request.
Scenario framework (business-planning format)
Because Duavee’s demand is persistence-driven and sensitive to payer access, projections typically bifurcate into two practical ranges:
| Variable |
Upside scenario |
Base case |
Downside scenario |
| Net price trend |
Limited rebate pressure |
Moderate contracting |
Aggressive rebate/formulary loss |
| Patient persistence |
Stable switch rates |
Gradual churn |
Faster switching to alternatives |
| Competitor displacement |
Limited |
Ongoing substitution |
Stronger displacement from other classes |
| Generic threat |
Delayed or narrow entry |
Controlled by patent/label |
Accelerated substitution if barriers fall |
How Duavee compares with competing therapies in clinical positioning
Bottom line: Duavee is typically compared against conventional hormone therapy approaches and osteoporosis drug classes, with the key differentiator being a tissue-selective approach intended to preserve uterine safety while supporting bone-related benefits.
Where Duavee fits in treatment algorithms
Answer: Duavee tends to be considered when clinicians prioritize:
- Skeletal protection goals
- Uterine safety concerns
- Patient preference for non-progestin endometrial management approaches (where appropriate)
Key takeaways
- Duavee’s latest clinically visible updates are not dominated by new late-stage registrational trials; the evidence base remains label-aligned and practice-driven.
- Market performance hinges on payer formulary access, net pricing, and persistence in a niche menopausal hormone therapy segment.
- Generic risk and exclusivity timing depend on the Orange Book patent-by-patent listing and any Paragraph IV activity; those facts must be enumerated to support litigation or entry planning.
- Business projections are scenario-driven: net price and formulary position are typically higher impact than incremental clinical studies.
FAQs
- Is Duavee still being studied in new Phase 3 trials?
- What is Duavee’s Orange Book patent list for each strength, and when do listed patents expire?
- Have any companies filed Paragraph IV ANDAs for Duavee, and what is the litigation timeline?
- How does Duavee’s uterine safety positioning affect switching versus estrogen-progestin regimens?
- What would a generic Duavee need for approval and what label carveouts could reduce uptake?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (Duavee product listing).
- ClinicalTrials.gov. Duavee (conjugated estrogens/bazedoxifene) search results.
- FDA. Drug Approval Package for Duavee (NDA label and review documents).
